A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Phase 1 Completed 64 enrolled Idorsia Pharmaceuticals Ltd.

RandomizedParallel-groupTriple-blindOther

Summary

This Phase 1 study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of ACT-1004-1239 in healthy subjects.

Timeline

Start: 2019-03-25
Primary completion: 2019-07-11
Completion: 2019-07-11

Publications

Huynh C, Seeland S, Segrestaa J, Gnerre C, Hogeback J, Meyer Zu Schwabedissen HE, Dingemanse J, Sidharta PN. Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data. Front Pharmacol. 2022 Mar 30;13:812065. doi: 10.3389/fphar.2022.812065. eCollection 2022.
Pouzol L, Baumlin N, Sassi A, Tunis M, Marrie J, Vezzali E, Farine H, Mentzel U, Martinic MM. ACT-1004-1239, a first-in-class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases. FASEB J. 2021 Mar;35(3):e21431. doi: 10.1096/fj.202002465R.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ACT-1004-1239	Unknown	1 mg	Oral
Subject	ACT-1004-1239	Unknown	10 mg	Oral
Subject	ACT-1004-1239	Unknown	100 mg	Oral

Indications

No indication recorded.